Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Search Results: Breast Cancer (18 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

BRCA Founder Outreach Study (BFOR)

Prevention:
Breast
Ovarian
Pancreatic
Prostate

BRCA Founder Outreach Study (BFOR)

BFOR is a research study looking at ways to make genetic testing easier. It offers BRCA testing at no cost to men and women age 25 or older, who have at least one Ashkenazi Jewish grandparent. The study is open to people who live in the Boston, New York, Los Angeles or Philadelphia metropolitan areas. For more information, visit the BFOR study website

Making Genetic Testing Accessible (MAGENTA)

Prevention:
Breast
Ovarian

Making Genetic Testing Accessible (MAGENTA)

The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer.

Researchers also want to learn how these strategies may improve your understanding of genetics, your ability to complete a quiz about genetics, and your quality of life.

For more information, visit the study website

IMProving Executive function Study

Quality of Life:
Breast Cancer Survivor
High Risk But No Cancer
Ovarian Cancer Survivor

IMProving Executive function Study

Dr. C. Neill Epperson and her research team at the Penn Center for Women's Behavioral Wellness are studying the effects of a stimulant medication called Vyvanse® on memory and attention in women who had surgery to remove their ovaries to lower their risk for ovarian cancer (risk-reducing salpingo-oophorectomy or RRSO).

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Treatment:
Breast

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation.

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

Treatment:
Breast

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of the study is to look at whether giving the PARP inhibitor olaparib in combination with the immunotherapy atezolizumab improves outcomes for patients compared to olaparib alone.  

 

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Treatment:
Breast
Ovarian
Prostate

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

The purpose of the study is to examine the anti-tumor activity and safety of the immuno-onology agent, avelumab in combination with the PARP inhibitor, talazoparib in patients with locally advanced  or metastatic triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, castration resistant prostate cancer (CRPC) solid, non-small cell lung cancer (NSCLC), and urothelial cancer (UC). The study is also open to people with other advanced solid tumors with a BRCA or ATM gene defect

Pembrolizumab in Advanced BRCA-mutated Breast Cancer

Treatment:
Breast

Pembrolizumab in Advanced BRCA-mutated Breast Cancer

 

This trial will evaluate the use of immunotherapy in people with advanced breast cancer associated with a BRCA mutation. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) single agent therapy in advanced BRCA-mutated breast cancer.

Visit clinicaltrials.gov for more information. 

Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation

Quality of Life:
Breast Cancer Survivor
High Risk But No Cancer

Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation

This is a clinical trial designed to test the effectiveness of laser procedures for treating vaginal symptoms associated with menopause.

Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer

Prevention:
Breast

Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better.

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) (PTW)

Quality of Life:
Breast Cancer Survivor

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) (PTW)

The Pathways to Wellness study focuses on wellness after breast cancer. Researchers are looking to compare two groups, a mindfulness meditation class and survivorship education class, and their impact on meeting the common needs of young survivors. 

MonaLisa Touch Study - Michigan

Quality of Life:
Breast Cancer Survivor
High Risk But No Cancer

MonaLisa Touch Study - Michigan

The aim of the study is to test the effectiveness of MonaLisa Touch laser procedure for treating vaginal symptoms associated with menopause.

Talazoparib Beyond BRCA (TBB) Trial

Treatment:
Breast

Talazoparib Beyond BRCA (TBB) Trial

The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. 

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

Prevention:
Breast

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

In this study, researchers want to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women.

Visit the study website for more information.

An Online Study of Memory and Attention in High-Risk Women

Quality of Life:
Breast Cancer Survivor
High Risk But No Cancer
Melanoma Cancer Survivor
Ovarian Cancer Survivor
Pancreatic Cancer Survivor

An Online Study of Memory and Attention in High-Risk Women

Overview of study

Several women with a BRCA1 or BRCA2 mutation have expressed concern that various surgery or treatment strategies might affect their memory or attention. In order to respond to their concerns, we plan to conduct a novel study to understand how various factors (including chemotherapy, hormone replacement therapy, and surgery) may influence memory and attention among high-risk women. The results will help us improve the way we manage all health aspects of women who are at high risk, especially as they age.

 

The WISDOM Study: Women Informed to Screen Depending on Measures of risk

Prevention:
Breast

The WISDOM Study: Women Informed to Screen Depending on Measures of risk

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website

Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer

Treatment:
Breast

Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer

This study is for with people with advanced breast cancer and a BRCA mutation or triple-negative breast cancer. This study is open to people with spread of the cancer to their brain or other places in their body. The study will compare whether adding the PARP inhibitor veliparib to the chemotherapy cisplatin improves response over chemotherapy alone. Veliparib is a PARP inhibitor that inhibits the ability of cancer cell to fix DNA damage caused by chemotherapy.  This drug combination could be important for patients who have brain metastasis because veliparib and cisplatin both cross the blood brain barrier. The goal of this study is to treat metastatic breast cancer within the brain and outside of the brain (i.e. in other parts of the body) at the same time. 

This study is important because most studies for people with metastatic breast cancer exclude patients who have spread to the brain. 

 

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (Inform)

Treatment:
Breast

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (Inform)

About the Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug Cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited mutation in BRCA1 or BRCA2. 

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation:  A Radiotherapy Comparative Effectiveness Trial

Treatment:
Breast

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

For more information, visit: RadComp.org

Additional Results on Clinicaltrials.gov: Breast Cancer

777 Results

Clinical Trial Official Title
NCT03596073 Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT03765983 GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT03483012 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
NCT03316586 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
NCT03495115 Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening
NCT02926729 Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT02999477 A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
NCT03473639 A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
NCT03789110 NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NCT03180086 Breast Cancer Risk Assessment in Women Aged 40-49
NCT03243331 An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NCT03783546 Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
NCT03130439 Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
NCT03761706 Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging
NCT03212170 FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
NCT00948285 Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer
NCT02352025 S-equol in Women With Triple Negative Breast Cancer
NCT03482557 Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening
NCT03366844 Breast Cancer Study of Preoperative Pembrolizumab + Radiation
NCT02564848 Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT03237572 Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
NCT03564782 Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer
NCT03964532 TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
NCT02653755 The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
NCT03025035 Pembrolizumab in Advanced BRCA-mutated Breast Cancer
NCT03694756 TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT03641755 Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
NCT03747042 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
NCT02956473 Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy
NCT00734838 Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy
NCT01943695 Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer
NCT03930797 Coping Together After Breast Cancer
NCT03546686 Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer
NCT02780271 Diet and Physical Activity Changes Among Latina Breast Cancer Survivors
NCT03612596 Narrative Visualization for Breast Cancer Survivors' Physical Activity
NCT03358511 Engineering Gut Microbiome to Target Breast Cancer
NCT02945579 Eliminating Surgery After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT02803593 To Enhance Breast Cancer Survivorship of Asian Americans
NCT02520063 Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
NCT03219476 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT03413332 Web-Based Communication Education for Breast Cancer Survivorship Care
NCT03770598 Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients
NCT03980093 The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors
NCT03093350 TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
NCT03400215 Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT02900469 Presurgical Trial of Denosumab in Breast Cancer
NCT03780491 Understanding and Addressing Patient and Provider Preferences Around Discussions of Cost of Breast Cancer Care
NCT03750240 Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
NCT03650803 Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer
NCT02842658 Exercise Preconditioning and Breast Cancer Cardiotoxicity
NCT02657343 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
NCT03344536 A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
NCT03573648 Neoadjuvant Tamoxifen, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03304587 Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors
NCT03400254 Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
NCT03696056 Improving Brain Function After Breast Cancer Study
NCT03225547 Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
NCT03186937 A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
NCT03383835 Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer
NCT03639948 Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT03092635 AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy
NCT02958774 Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT00909909 Radiation Therapy in Treating Women With Early Stage Breast Cancer
NCT03632941 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT03624972 Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
NCT02482376 Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
NCT02734290 Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
NCT02370797 Node Negative, Invasive Breast Cancer Single Fraction IOERT
NCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
NCT02619669 Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
NCT02696759 Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
NCT02510456 Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging
NCT02626507 Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
NCT02834403 L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
NCT03719677 Reducing Metabolic Syndrome Among Breast Cancer Survivors
NCT02489448 Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
NCT03045289 A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer
NCT02666378 Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
NCT03683147 Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer
NCT02599363 A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
NCT02789657 BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
NCT02913430 Phase II Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
NCT03863522 Automated Method for Breast Cancer Detection
NCT02682836 Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study
NCT03733119 ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
NCT02732171 PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT03032406 CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
NCT01975597 Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer
NCT02623972 A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT03510988 Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer
NCT02788981 Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
NCT02694029 Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer
NCT03167619 Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
NCT02400658 Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer
NCT03193853 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
NCT02776917 Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
NCT03988595 Exercise Treatment With Standard Therapy for Metastatic Breast Cancer
NCT03125928 Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT01676753 Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
NCT02019303 Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer
NCT03911453 Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT03837496 Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
NCT02494869 Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer
NCT03043794 Study of Stereotactic Radiotherapy for Breast Cancer
NCT02750241 Pink Warrior—Support Group Toolkit for Breast Cancer Survivors
NCT01980823 Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
NCT03069742 Study of Web-based Decision Aids for Increasing Breast Cancer Chemoprevention in the Primary Care Setting
NCT03535701 Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
NCT03094052 Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy
NCT03874325 Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
NCT03339518 Breast Cancer Recurrence Risk Counseling
NCT02188745 ER Reactivation Therapy for Breast Cancer
NCT02744079 Comparison of Healthy Diets on Breast Cancer Markers
NCT03807765 Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
NCT02719691 Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
NCT02608216 [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
NCT03112590 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
NCT01976169 Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
NCT03027063 Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.
NCT02409316 [18F]FES PET/CT in Endocrine Refractory Breast Cancer
NCT02642094 Aging Mammary Stem Cells and Breast Cancer Prevention
NCT03253627 MBSR During AI Therapy for Breast Cancer
NCT02781805 Pilot Study of Bisphosphonates for Breast Cancer
NCT03121352 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
NCT02866994 Project Connect Online: An Internet-based Intervention for Women With Breast Cancer
NCT01035099 RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
NCT03018080 Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
NCT02652923 Contrast Ultrasound Detection of Sentinel Lymph Nodes
NCT03661424 BATs in Patients With Breast Cancer and Leptomeningeal Metastases
NCT03394027 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
NCT03654547 Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
NCT03252431 Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
NCT03176979 Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer
NCT03429907 An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
NCT02348320 Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
NCT02427581 Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT03032107 A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
NCT03609671 Emotions Immunology and Breast Cancer
NCT02401347 Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors
NCT02827370 CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer
NCT03439735 Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC
NCT03137693 Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
NCT03703492 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
NCT02823262 A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
NCT03106077 Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
NCT03207529 Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
NCT02876107 A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
NCT01372631 A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins
NCT02965755 Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
NCT02204098 Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
NCT03650894 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT02286843 Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
NCT03612648 Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma
NCT02124902 Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
NCT03858972 Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
NCT03065712 Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET
NCT03729115 A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT03592771 THRIVE Breast Cancer App Study
NCT03149081 A "Window Trial" on Boswellia for Breast Cancer Primary Tumors
NCT02993198 A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
NCT02942355 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT03620201 M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT02324387 Tc99m Sestamibi Molecular Breast Imaging
NCT02328313 Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients
NCT03831711 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
NCT02754752 Trial of Acupuncture for Chronic Pain After Breast Cancer Treatment
NCT03292536 Merestinib on Bone Metastases in Subjects With Breast Cancer
NCT01698658 Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer
NCT03718455 Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes
NCT02871791 Palbociclib With Everolimus + Exemestane In BC
NCT03567044 Immune Effects in Patients Treated With Whole Breast Irradiation
NCT03594578 Prospective Thinking in Hormone-Responsive Breast Cancer
NCT02793921 Exercise Program in Cancer and Cognition
NCT03679559 Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
NCT02996240 Breast, Omega 3 Free Fatty Acid, Ph 0
NCT03243786 Stay on Track: A Study of Exercise Effects During Radiation
NCT03789877 A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity
NCT03769415 Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT02647216 Mindfulness for Breast Cancer
NCT03199040 Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
NCT03292198 Subclinical Lymphedema Treatment Study
NCT03200704 A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer
NCT02639208 Novel Social Media Intervention For Older Br CA Patients
NCT03498157 IMpact of PRehabilitation in Oncology Via Exercise - Breast Cancer
NCT03787303 Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
NCT03975621 Nurse AMIE: Addressing Metastatic Individuals Everyday
NCT03460067 Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT03091647 Acupressure for Cancer-Related Fatigue
NCT03365895 Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)
NCT02476786 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT03361800 Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
NCT03285412 CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer
NCT02953860 Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
NCT03655600 Acupressure for Pain and Opioid Use Among Breast Cancer Patients
NCT03581136 Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
NCT03661892 Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets
NCT02779855 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT02531932 Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
NCT02538484 Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
NCT02939274 An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
NCT01755208 Light-Scattering Spectroscopy for Detection of Breast Cancer
NCT01839838 APBI Proton Feasibility and Phase II Study
NCT02824575 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT02955394 Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
NCT02390427 Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
NCT02912312 Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT02547987 Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
NCT03007979 Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
NCT03599453 Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
NCT01984138 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
NCT02936206 Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
NCT03190967 T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
NCT03779867 Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants
NCT03362060 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT02479230 Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
NCT03329378 Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
NCT02685332 Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
NCT03449303 Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention
NCT03854903 WI231696: ASPIRE Bosutinib
NCT01960803 Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)
NCT03941743 Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer
NCT03524170 Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT03387553 HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT02186470 Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
NCT01897441 Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
NCT03154281 Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast
NCT03393845 Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
NCT03544125 Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
NCT03579472 M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03135171 Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT02203513 A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
NCT03955640 Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
NCT02068092 Olive Oil for High Risk Breast Cancer Prevention in Women
NCT03367572 Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT03012399 Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery
NCT03853707 Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03199560 Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy
NCT03723863 Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy
NCT02454777 High-Intensity Interval Training for Stage I-III Breast Cancer Patients
NCT03955991 VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
NCT03454529 The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer
NCT03523195 Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors
NCT03941756 Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT02658812 Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
NCT03102866 Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
NCT03786354 Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer
NCT02157051 Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT02315196 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
NCT03774472 Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT02760030 Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT03806738 Enhancing Shared Decision-Making in Breast Cancer
NCT03566485 Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
NCT02964234 Empowering Latinas to Obtain Breast Cancer Screenings
NCT02436993 Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
NCT02971748 Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
NCT02536794 MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
NCT03858322 'ADVANCE' (A Pilot Trial)
NCT03801369 Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer
NCT03417544 Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
NCT03751449 Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors
NCT03747120 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
NCT00625417 Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
NCT03557554 Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy
NCT03364348 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
NCT02672475 Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT03106415 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT01912612 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients With Chronic Pain
NCT03128619 Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
NCT03897270 Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
NCT02515110 Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
NCT03501979 Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
NCT02780401 Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
NCT02689427 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
NCT03487601 Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function
NCT03216421 Intraoperative Radiation Therapy (IORT) in DCIS
NCT03101748 Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT03952325 Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC
NCT03294694 Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
NCT02827877 Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer
NCT03384914 Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
NCT03505671 Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
NCT03872388 Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
NCT03838367 Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
NCT03202316 Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT02411656 Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
NCT03252145 Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device
NCT02946697 A Culturally Sensitive Social Support Intervention
NCT03280836 Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT03657069 Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy
NCT01697293 Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
NCT03573804 The Prone to Supine Breast MRI Trial
NCT03592121 Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
NCT02690116 Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
NCT02530489 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT02927912 Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT03539835 Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors
NCT02513329 Stellate Ganglion Block (SGB) For Women for Breast Cancer
NCT03143894 Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation
NCT03345420 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT03901339 Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)
NCT03004183 SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT02831582 Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer
NCT03257670 Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors
NCT03167359 Hypofractionated Radiotherapy in Breast Cancer
NCT02751528 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NCT03645005 A Research Study for Latina Women After Breast Cancer Treatment
NCT02335671 Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
NCT03323658 Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
NCT02796755 Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation
NCT02095184 GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT02728076 MRI-Based Preoperative Accelerated Partial Breast Irradiation
NCT02203552 Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
NCT02957968 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
NCT03542604 Cancer, Obesity/Overweight and Insomnia Study
NCT03573661 A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers
NCT03179904 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer
NCT02422641 Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT02540330 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
NCT01688388 Single Fraction Intraoperative Radiotherapy
NCT02654119 Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery
NCT02415387 Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
NCT03025139 Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT03684408 Radiofrequency Chip for Localization of Non-Palpable Breast Lesions
NCT02996825 Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
NCT02910219 Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
NCT02276885 Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial
NCT03685175 Effect of Cardiotoxic Anticancer Chemotherapy on the Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria
NCT02033486 Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)
NCT03314688 Lifestyle, Exercise, and Nutrition Study Early After Diagnosis
NCT03060356 Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
NCT03201913 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
NCT02763228 Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors
NCT03096418 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT02844504 Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness
NCT03865992 Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease
NCT03225170 Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling
NCT03845907 Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
NCT03822715 NEOBREADS: Neoadjuvant Breast Diet Study
NCT03667560 Dermacell ADM Without Basement Membrane
NCT02926690 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT03442127 Facilitating Oncology Patient-Clinician Communication Via E-health Innovations
NCT03393117 Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction
NCT03354611 Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging
NCT03321045 PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT03281720 Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases
NCT03238976 Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
NCT03152929 Paravertebral Block Versus Pectoral Nerve Block
NCT02917421 Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations
NCT02891759 Compare Outcomes Between Two Acellular Dermal Matrices
NCT02883387 CT-Angiography Prior to DIEP Flap Breast Reconstruction
NCT02802553 Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions
NCT02739620 Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors
NCT02725801 Comparison of One-port and Two-port Tissue Expanders for Breast Reconstruction
NCT03139435 Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
NCT02613416 Denosumab and MRI Breast Imaging
NCT02439437 Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain
NCT02395614 Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation
NCT02317783 Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
NCT02593175 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
NCT02035085 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction
NCT01916122 Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
NCT03084536 PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
NCT03359954 PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects
NCT00734955 An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients
NCT02818946 Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial
NCT03360214 PEMF and PEC Blocks in Mastectomy Reconstruction Patients
NCT02726763 Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training
NCT02876640 Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
NCT03709446 Leflunomide in Previously Treated Metastatic Triple Negative Cancers
NCT02707471 Improving Well-Being for Breast Cancer Patients
NCT03448003 Comprehensive Lifestyle Change To Prevent Breast Cancer
NCT02970344 I HEAL for Breast Cancer Survivors With Diabetes
NCT03725436 ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
NCT02332928 Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy
NCT03487666 OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
NCT03909282 Phase II Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT02456857 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
NCT03158519 iMETX (Individualized Metabolic RX): a Pilot Study
NCT03122301 Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer
NCT03217201 Systematic Light Exposure for Fatigue in Breast Cancer Patients
NCT03120390 Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors
NCT03375892 A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure
NCT02571530 Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
NCT01554371 Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT02511301 Circadian Thermal Sensing to Detect Breast Disease
NCT02657993 Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
NCT03775850 A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
NCT03562273 GammaPod Registry and Quality of Life Nomogram
NCT01730118 Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
NCT02755896 Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
NCT03630601 Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers
NCT02918474 Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
NCT03796273 Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT03624478 Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
NCT03324802 Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery
NCT03744715 A Study to Allow Continued Treatment of Patients Who Have Participated in a Spectrum-Sponsored Poziotinib Study
NCT02826434 Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
NCT02786797 Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors
NCT02474173 Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
NCT02738866 Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT01245712 Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT03706534 Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms
NCT03560531 A Study of ZN-c5 in Subjects With Breast Cancer
NCT01618357 Pre-Operative Radiation and Veliparib for Breast Cancer
NCT03326713 Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project
NCT03709082 Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT02341235 Self-monitoring Activity: a Randomized Trial of Game-oriented Applications
NCT03060941 Promoting Activity in Cancer Survivors
NCT01750073 Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer
NCT02605486 Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
NCT03716180 DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
NCT02484404 Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
NCT02907918 Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
NCT01766297 Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT01723774 PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT03642990 NR in Chemo-induced Peripheral Neuropathy
NCT01185132 Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT02891681 Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
NCT03088527 Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
NCT02194387 Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
NCT03328026 Combination Study of SV-BR-1-GM in Combination With Pembrolizumab
NCT03630809 Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
NCT03292328 Yoga for Symptoms of Nerve Damage Caused by Chemotherapy
NCT02755272 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT03238495 Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT03572374 Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT03238196 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
NCT03054363 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
NCT03471663 A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
NCT01824836 A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
NCT03451162 Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer
NCT02521363 Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
NCT03953326 HeartPhone Cancer Survivors Trial 2019
NCT02598557 Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
NCT03567720 Intratumoral Tavo and Pembro in Patients With Inoperable Locally Advanced or Metastatic TNBC (KEYNOTE-890)
NCT03651037 Physical Activity Platform to Improve Bone Health in Cancer Survivors
NCT03178383 Integration of Cancer Health Activities Into African American Churches
NCT03304080 Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast
NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
NCT03289039 Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
NCT02106598 Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
NCT03414658 The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
NCT03572153 A Mind-Body Intervention for Hot Flash Management
NCT03587740 ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
NCT03289195 Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer
NCT01724606 Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
NCT02764541 Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
NCT03499353 Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
NCT02791581 Understanding and Predicting Breast Cancer Events After Treatment
NCT03861403 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
NCT03241810 Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
NCT03523585 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03529110 DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03542175 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
NCT02876302 Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT01990209 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
NCT02712723 Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
NCT01969643 A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
NCT01674140 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT03056755 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03377387 Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
NCT03778931 Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
NCT02236000 A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NCT03701334 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03628066 Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NCT03488693 Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NCT03734029 DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT02574455 ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer
NCT03255577 Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
NCT02206984 Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT02947685 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT03822468 Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
NCT02632045 Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
NCT03726879 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
NCT03284957 Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
NCT03725059 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03337724 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT03326102 Oral Paclitaxel Efficacy Safety and PK in Recurrent and metAstatic Breast Cancer
NCT01992250 Cryoablation of Small Breast Tumors in Early Stage Breast Cancer
NCT02603341 Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
NCT02393794 Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT02957981 The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
NCT01494662 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
NCT03321929 Intraoperative Detection of Residual Cancer in Breast Cancer
NCT03262935 SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT02980341 Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
NCT03916744 A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
NCT03195192 Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
NCT03781063 Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation
NCT03514433 Translating Research Into Practice
NCT02308085 Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
NCT03321981 MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer
NCT03616587 Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer
NCT03077841 Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
NCT03422003 Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
NCT03281954 Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03562637 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.
NCT03498716 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
NCT03197935 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03125902 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
NCT01901094 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
NCT03598257 Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT02993068 Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
NCT03674112 A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
NCT03255070 A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
NCT03284346 Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors
NCT02792114 T-Cell Therapy for Advanced Breast Cancer
NCT02927249 Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02734615 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
NCT03407716 Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
NCT02400476 A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
NCT03421782 Fatigue Interventions in Cancer (Exercise Intervention)
NCT02422498 Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
NCT02915744 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
NCT03470402 Decision Support for BRCA Testing in Ethnically Diverse Women
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE)
NCT03095352 A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT02620852 Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
NCT02744053 DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
NCT03647189 Randomized, Controlled Trial With Hybrid Fractional Laser
NCT03006172 To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03873272 The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL
NCT03280563 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
NCT02057133 A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT01670877 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT01928589 Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer
NCT03659136 The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
NCT02750826 Breast Cancer WEight Loss Study (BWEL Study)
NCT03584009 A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT03310541 AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
NCT03742102 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.
NCT02107703 A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT03070340 Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery
NCT03371017 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT03326674 Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
NCT02648477 Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
NCT03766009 Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making
NCT01802346 Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
NCT02779751 A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT03206203 Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT02276443 Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT03875313 Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
NCT03800836 A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT03433313 Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
NCT01872975 Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
NCT03344965 Olaparib In Metastatic Breast Cancer
NCT01570998 Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT03499899 A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
NCT03834532 Living Well After Breast Surgery
NCT03530696 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
NCT03653988 Comparison of Pre-op and Post-op Pectoralis Nerve Block
NCT03330847 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03099174 This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
NCT03419741 Brain Stimulation For Cancer Smokers
NCT03233555 Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
NCT03256344 A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
NCT03630354 EXERCISING TOGETHER© for Couples Coping With Cancer
NCT03168737 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
NCT02978586 A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
NCT03574194 Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy
NCT03455270 G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer
NCT02778685 Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
NCT01805076 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT02668666 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
NCT03250676 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
NCT02310464 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
NCT01042379 I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT03723928 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03719326 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies
NCT02860000 Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
NCT02453620 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT02398773 FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
NCT02849496 Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
NCT02971761 Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
NCT01989546 Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
NCT02595320 Capecitabine in Metastatic Breast and GI Cancers
NCT03113825 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
NCT02445391 Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
NCT02883062 Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
NCT02488967 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02964507 Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
NCT03162627 Selumetinib and Olaparib in Solid Tumors
NCT03428802 Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT02595905 Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
NCT03694249 Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
NCT02954874 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT01037790 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER
NCT03199885 Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
NCT03418961 S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03674827 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
NCT01953588 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT02364557 Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
NCT01622868 Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
NCT02013492 Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
NCT02897375 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT03691493 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
NCT03511690 Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment
NCT03135782 Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy
NCT02408406 PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers
NCT01792726 A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
NCT02898207 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
NCT01552434 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
NCT03524430 RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY
NCT03329937 Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment
NCT02874430 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
NCT01884285 AZD8186 First Time In Patient Ascending Dose Study
NCT03154190 Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
NCT02595372 Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
NCT02900664 A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
NCT03300843 Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
NCT03351348 Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT01376505 Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT02706392 Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
NCT03829436 TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
NCT02406599 MarginProbe® System U.S. Post-Approval Study
NCT03412877 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
NCT01967823 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT03195322 Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction
NCT02639026 Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
NCT03272919 Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT02111850 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
NCT03519178 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
NCT01624090 Mithramycin for Lung, Esophagus, and Other Chest Cancers
NCT00984321 A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer
NCT01920061 A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
NCT03317405 Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
NCT02890069 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
NCT03414970 Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03685591 PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
NCT03011684 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT03604315 Fluorine F 18 Fluorthanatrace PET/CT in Treating Participants With Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03862131 PROactive Evaluation of Function to Avoid CardioToxicity
NCT03518138 Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor
NCT03218826 PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
NCT03523572 Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer
NCT03291938 IACS-010759 in Advanced Cancers
NCT03282097 Decisions About Cancer Screening in Alzheimer's Disease
NCT03303846 Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients
NCT03063619 Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
NCT01905046 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
NCT03652077 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
NCT02264678 Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT03476681 QUILT-3.017: Study of NEO-201 in Solid Tumors
NCT03360695 Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
NCT03808662 Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
NCT03877146 Calming Alternatives Learned During MRI-Guided Breast Biopsy
NCT02993159 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
NCT03065387 Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation
NCT03535506 Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
NCT03808337 Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03343613 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
NCT03164486 First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
NCT02928978 Ruxolitinib for Premalignant Breast Disease
NCT03435952 Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT02638935 Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions
NCT02464696 Early Non Invasive Ventilation and Hematological Malignancies
NCT03221400 PEN-866 in Patients With Advanced Solid Malignancies
NCT03716050 The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems
NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors
NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
NCT02822573 Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
NCT02694809 The PROMISE Study: Duavee in Women With DCIS
NCT03195699 Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
NCT03552718 QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NCT02922127 Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation
NCT00579514 Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
NCT03960463 EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT00967577 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
NCT02807844 Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
NCT03841110 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT03339765 Self-Advocacy Serious Game in Advanced Cancer
NCT02627274 A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
NCT01295723 Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)
NCT03134638 A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors
NCT03076372 A Study Evaluating MM-310 in Patients With Solid Tumors
NCT03094169 AVID100 in Advanced Epithelial Carcinomas
NCT03773133 Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
NCT03233191 Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
NCT03284723 PF-06804103 Dose Escalation in HER2 Positive Solid Tumors
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT03199586 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)
NCT03775525 Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
NCT03576131 GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
NCT03621982 Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
NCT03678883 9-ING-41 in Patients With Advanced Cancers
NCT03319459 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
NCT02983045 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
NCT03650348 PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
NCT03330561 PRS-343 in HER2-Positive Solid Tumors
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03514121 FPA150 in Patients With Advanced Solid Tumors
NCT02500199 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
NCT03409458 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
NCT02991677 Exercise Effect on Chemotherapy-Induced Neuropathic Pain
NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT02655822 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
NCT02728596 S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
NCT02643303 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
NCT03454451 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
NCT03667716 COM701 in Subjects With Advanced Solid Tumors
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT02637531 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
NCT02498613 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT03602079 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT03435640 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT03549000 A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
NCT03289962 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03170960 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03829501 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
NCT03207867 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
NCT03717415 A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
NCT02414269 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
NCT03330405 Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
NCT03517488 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03075540 Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer
NCT02872025 Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
NCT00986661 A Study to Assess PV-10 Chemoablation of Cancer of the Liver
NCT03505372 Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
NCT02791334 A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02890368 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
NCT03180294 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NCT03129139 A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03058289 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
NCT03717402 Smartphone Technology to Alleviate Malignant Pain (STAMP)
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02947165 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
NCT03075072 Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial
NCT03149549 PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
NCT03629756 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
NCT03329950 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT02628535 Safety Study of MGD009 in B7-H3-expressing Tumors
NCT02393248 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
NCT03628677 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
NCT03821233 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
NCT03680560 Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
NCT03899792 A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
NCT03250832 Study of TSR-033 With an Anti-PD-1
NCT03601897 A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
NCT03069469 Study of DCC-3014 in Patients With Advanced Tumors
NCT02762981 Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
NCT03157128 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
NCT02760849 Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
NCT02926911 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
NCT03102320 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
NCT02052778 A Study of TAS-120 in Patients With Advanced Solid Tumors
NCT02892123 Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
NCT03565445 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
NCT02783300 Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
NCT03595059 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
NCT02734004 A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
NCT02922764 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
NCT03150810 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT02650401 Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors And Primary Cns Tumors, With or Without Trk, Ros1, or Alk Fusions
NCT03000257 A Study of ABBV-181 in Participants With Advanced Solid Tumors
NCT03071757 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03126110 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT02554812 A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
NCT03821935 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

FORCE:Facing Our Risk of Cancer Empowered